Stopping Wegovy or Zepbound? How to Keep Weight Off


  • A Cleveland Clinic study found that bariatric surgery and switching GLP-1 medications were associated with greater weight loss than discontinuing treatment entirely.
  • After two years, participants who underwent bariatric surgery lost an average of 28.2% of their body weight, compared with 16% among those who switched between semaglutide and tirzepatide and 4% among those who stopped GLP-1 treatment.
  • Stopping a GLP-1 medication can lead to increased hunger and weight regain. Experts recommend working with a healthcare professional to develop a long-term weight management plan before discontinuing treatment.

Switching GLP-1 medications or undergoing bariatric surgery may help people maintain greater weight loss than stopping treatment entirely, according to a new study presented at ObesityWeek and published in eClinicalMedicine on November 14.

The Cleveland Clinic study compared five strategies for managing weight after treatment with GLP-1 medications, analyzing data from 20,486 adults with obesity or type 2 diabetes.

People who stop taking GLP-1 medications often regain weight. Researchers examined whether continuing treatment, switching medications, or undergoing bariatric surgery could help limit weight regain or support further weight loss.

The findings showed that people who underwent bariatric surgery or switched between semaglutide (Ozempic) and tirzepatide (Zepbound) experienced the greatest overall weight loss.

The study participants had an average age of 56.7 years, an average weight of 109 kg (240.3 lbs), and an average body mass index (BMI) of 38. All had been taking either semaglutide or tirzepatide for at least 90 days.

The researchers categorized the participants into five groups:

  • continuation
  • switching between semaglutide and tirzepatide
  • switching to another weight-loss medication
  • undergoing bariatric surgery
  • discontinuation

After 2 years, those who underwent bariatric surgery saw an average loss of 28.2% of their body weight or about 31.5 kg (69.4 lbs).

“We increasingly view medications and surgery as complementary tools rather than competing ones,” said Mir Ali, MD, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, who wasn’t involved in the study.

“For patients with severe obesity (typically a BMI of 35 or higher, or 30+ with metabolic conditions like type 2 diabetes), bariatric surgery remains the most durable, cost-effective intervention available,” he added. “Using a GLP-1 beforehand can safely reduce liver volume and lower surgical risk, while surgery provides the permanent anatomical and hormonal reset needed to maintain that weight loss long-term without relying indefinitely on weekly injections.”

During the same period, those who switched between semaglutide and tirzepatide lost 16% of their body weight, or about 18 kg (39.6 lbs).

Participants who switched from semaglutide to tirzepatide lost 3 kg (6.6 lbs) more than those who continued taking semaglutide. However, participants already taking tirzepatide lost 4.5 kg (9.9 lbs) more by continuing treatment rather than switching to semaglutide.

The other groups experienced lower amounts of weight loss:

  • Continuation of initial GLP-1 medication: average of 10.9% of their body weight or 12.3 kg (27.1 lbs)
  • Switching to another weight loss medication: average of 8.2% of their body weight or 9.2 kg (20.2 lbs)
  • Total discontinuation of a GLP-1 medication: average of 4% of their body weight or 4.5 kg (9.9 lbs)

After one year, participants with type 2 diabetes experienced HbA1c reductions of 1.76% following bariatric surgery, 1.43% after switching GLP-1 medications, and 1.32% after continuing their original medication, compared with 0.48% among those who discontinued treatment entirely.

After one year, participants with hypertension (high blood pressure) also experienced greater reductions in blood pressure following surgery or switching GLP-1 medications than those who discontinued treatment entirely.

“[This study] reinforces the need for a long term, multi-modal continuum of care rather than treating GLP-1s as a temporary fix,” said Ali.

The findings highlight the importance of having a long-term weight management plan in place before stopping a GLP-1 medication.

Before stopping a GLP-1 medication, talk with a healthcare professional. They can help you explore your options and determine which strategies may be most appropriate for your health needs.

Ali told Healthline that identifying the reason for stopping treatment is an important first step. He noted that people often discontinue GLP-1 medications because of gastrointestinal side effects, supply issues, or loss of insurance coverage rather than because they no longer need treatment.

He said that if side effects are the issue, adjusting the dose or switching to a different agent often solves the problem.

Ali also emphasized that stopping a GLP-1 medication shouldn’t be viewed as a test of willpower. Increased hunger after discontinuing treatment is a biological response, not a personal failure.

“Have a concrete ‘off-ramp’ plan in place with your doctor before taking your last dose, so you have medical, nutritional, or surgical support ready to protect the health gains you worked hard to achieve,” advised Ali.



Source link